Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

By P. Rosenfeld, A. Moshfeghi, C. Puliafito. Ophthalmic surgery, lasers & imaging, 2005

966 citations recorded by the source corpus.

Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2207add4d3bbbfa1e1d3b3da6e7aff7a9031d75b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ophthalmology

1. Don H. Anderson
2. L. V. Johnson
3. G. Hageman

In Radiology, Nuclear Medicine and Imaging

1. L. V. Johnson
2. Don H. Anderson
3. G. Hageman

Citations in the corpus

• Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts (2006, background): “It is important to note that Avastin has not yet undergone the toxicity studies and controlled trials that are required by the FDA for ocular application (58,59).”
• Recent developments in optical coherence tomography for imaging the retina. (2007, background): “, 2006a) or in monitoring the effect of recently introduced antiangiogenic drugs (Rosenfeld et al., 2005; Michels et al., 2005; Avery et al., 2006).”
• DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006, neutral): “terminal domain (111-165) of vascular endothelial growth”